Role of anti-inflammatory drugs in the treatment of acute coronary syndromes. From athero-inflammation to athero-thrombosis;Papel de los antiinflamatorios en el tratamiento de los síndromes coronarios agudos. De la ateroinflamación a la aterotrombosis

Revista Espanola de Cardiologia

Volumn 56, Issue 1, 2003, Pages 9-15

  Altman, Raúl ^a   Scazziota, Alejandra ^a  

^a UNIVERSIDAD NACIONAL DE TUCUMÁN   (Argentina)

Author keywords

Acute coronary syndromes; Athero inflammation; Athero thrombosis; Non steroidal anti inflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; HEPARIN; IBUPROFEN; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ATHEROSCLEROTIC PLAQUE; CAUSE OF DEATH; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY THROMBOSIS; CORONARY CARE UNIT; DISEASE SEVERITY; EDITORIAL; ENZYME INHIBITION; GASTRITIS; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INFLAMMATION; MORBIDITY; MORTALITY; PATHOGENESIS; PATHOPHYSIOLOGY; PILOT STUDY; PROGNOSIS; ST SEGMENT ELEVATION;

EID: 0037282836     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13042335     Document Type: Editorial

References (62)

1. DeWood MA, Spores J, Notske R, Mouser LT, Burroughs T, Golden MS, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980;303:897-902.
2. Mehta JL, Saldeen TGP, Rand K. Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease. J Am Coll Cardiol 1998;31:1217-25.
3. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-9.
4. Falk E, Shah PK, Fuster V. Coronary plaque rupture. Circulation 1995;92:657-71.
5. Falk E. Coronary thrombosis: pathogenesis and clinical manifestations. Am J Cardiol 1991;68:28B-35B.
6. Mizuno K, Miyamoto A, Satomura K, Kurita A, Arai T, Sakurada M, et al. Angioscopic coronary macromorphology in patients with acute coronary disorders. Lancet 1991;337:809-12.
7. Sinapius D. Morphology of occlusive coronary thrombi. Localization, lenght, composition, growth. Dtsch Med Wochrenschr 1972;97:544-6.
8. Van Belle E, Lablanche JM, Bauters CH, Renaud N, McFadden EP, Bertrand ME. Coronary angioscopic findings in the infarct-related vessel within 1 month of acute myocardial infarction. Natural history and the effect of thrombolysis. Circulation 1998;97:28-33.
9. Ross R. Atherosclerosis. An inflammatory disease. N Engl J Med 1999;340:115-26.
10. Libby P, Mach F, Schönbeck U, Bourcier T, Aikawa M. Regulation of the thrombotic potential of atheroma. Thrombos Haemost 1999;82:736-41.
11. Mann JM, Kaski JC, Pereira WI, Arie S, Ramires JA, Pileggi F. Histological patterns of atherosclerotic plaques in unstable angina patients vary according to clinical presentation. Heart 1998;80:19-22.
12. Farb A, Burke AP, Tang AL, Liang Y, Poonam Mannan MS, Smialek J, et al. Coronary plaque erosion without rupture into a lipid core. Circulation 1996;93:1354-63.
13. Verheggen PW, De Maat MP, Cats VM, Haverkate F, Zwinderman AH, Kluft C, et al. Inflammatory status as a main determinant of outcome in patients with unstable angina, independent of coagulation activation and endothelial cell function. Eur Heart J 1999;20:567-74.
14. Azar RR, Waters DD. The inflammatory etiology of unstable angina. Am Heart J 1996;132:1101-6.
15. Serneri GG, Abbate R, Gori AM, Attanasio M, Martini F, Giusti B, et al. Transient intermittent lymphocyte activation is responsible for the instability of angina. Circulation 1992;86:790-7.
16. Waltenberger J. Pathophysiological basis of unstable coronary syndrome. Herz 2001;26(Suppl 1):2-8.
17. Lijnen HR. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 2001;86:324-33.
18. Herman MP, Sukhova GK, Libby P, Gerdes N, Tang N, Horton DB, et al. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma. A novel collagenolytic pathway suggested by transcriptional profiling. Circulation 2001;104:1899-904.
19. Rajavashisth TB, Xu XP, Jovinge S, Meisel S, Xu XO, Chai NN, et al. Membrane type I matrix metalloproteinase expression in human atherosclerotic plaques: evidence for activation by pro-inflammatory mediators. Circulation 1999;99:3103-9.
20. Maseri A. Inflammation, atherosclerosis, and ischemic events. Exploring the hidden side of the moon. N Engl J Med 1997;336:1014-6.
21. Schoenhagen P, Tuzcu M, Ellis SG. Plaque vulnerability, plaque rupture, and acute coronary syndromes. (Multi)-focus manifestation of a systemic disease process. Circulation 2002;106:760-2.
22. Moreno PR, Bernardi VH, López-Cuéllar J, Murcia AM, Palacios IF, Gold HK, et al. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation 1996;94:3090-7.
23. Rioufol G, Finet G, Ginon I, Andre-Fouet X, Rossi R, Vialle E, et al. Multiple atherosclerotic plaque rupture in acute coronary syndrome. Athree-vessel intravascular ultrasound study. Circulation 2002;106:804-8.
24. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B, for the ROXIS Study group. Randomized trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. Lancet 1997;350:404-7.
25. Muhlestein JB, Anderson JL, Carlquist JF, Salunkhe K, Horne BD, Pearson RR, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease. Primary clinical results of the ACADEMIC study. Circulation 2000;102:1755-60.
26. Sinisalo J, Mattila K, Valtonen V, Anttonen O, Juvonen J, Melin J, et al. Effect of 3 months of antimicrobial treatment with clarithromicin in acute non-Q-wave coronary syndrome. Circulation 2002;105:1555-60.
27. Stone AF, Mendall MA, Kaski JC, Edger TM, Risley P, Poloniecki J, et al. Effect of Treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). Circulation 2002;106:1219-23.
28. Altman R, Rouvier J, Scazziota A, González C. No causal association between inflammation and Chlamydia Pneumoniae in patients with chronic ischemic arterial disease. Inflammation 2002;26:25-30.
29. De Boer OJ, Van der Wal, Becker AE. Atherosclerosis, inflammation, and infeccion. J Pathol 2000;190:237-43.
30. Matthay MA. Severe sepsis. A new treatment with both anticoagulant and antiinflamatory properties. N Engl J Med 2001;344:759-62.
31. Shebuski RJ, Kilgore KS. Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther 2002;30:729-35.
32. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The pronostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994;331:417-24.
33. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Cir Res 2001;89:763-71.
34. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
35. Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J, et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002;106:24-30.
36. Pasceri V, Willerson JT, Yeh ETH. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165-8.
37. Merlini PA, Repetto A, Lombardi A, Vetrano A, Fetiveau R, Cavallini C, et al. Effect of abciximab on prothrombin activation and thrombin generation in acute coronary syndromes without ST-segment elevation: global utilization of strategies to open occluded coronary arteries Trial IV in Acute Coronary Syndromes (GUSTO IV ACS) Italian hematologic substudy. Circulation 2002;105:928-32.
38. Bijsterveld NR, Moons AH, Meijers JC, Tijssen JG, Buller HR, Levi M, et. al. Rebound thrombin generation after heparin therapy in unstable angina. A randomized comparison between unfractionated and low-molecular-weight heparin. J Am Coll Cardiol 2002;39:811-7.
39. Lincoff AM, Kereiakes DJ, Mascelli MA, Deckelbaum LI, Barnathan ES, Patel KK, et al. Abciximab suppress the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 2001;104:163-7.
40. Bhatt DL, Topol EJ. Need to test the arterial inflammation hypothesis. Circulation 2002;106:136-40.
41. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll-like receptors in human atherosclerotic lesions. A possible pathway for plaque activation. Circulation 2002;105:1158-61.
42. Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002;347:185-92.
43. Woodhouse PR, Khaw KT, Plummer M, Foley A, Meade TW. Seasonal variations of plasma fibrinogen and factor VII activity in the elderly: winter infections and death from cardiovascular disease. Lancet 1994;343:435-9.
44. Van Lenten BJ, Wagner AC, Navab M, Fogelman AM. Acute influenza A infection promotes increased macrophage infiltration into the artery wall that is prevented by apolipoprotein A-1. Circulation 2001;104(Suppl 2):97.
45. Naghavi M, Barlas Z, Siadaty S, Naguib S, Madjid M, Casscells W. Association of influenza vaccination and reduced risk of recurrent myocardial infarction Circulation 2000;102:3039-45.
46. Gurfinkel EP, De la Fuente RL, Mendiz O, Mautner B, for the FLUVACS Study Group. Influenza vaccine pilot study in acute coronary syndromes and planned percutaneous coronary interventions. The FLU Vaccination Acute Coronary Syndromes (FLUVACS) study. Circulation 2002;105:2143-7.
47. Vane JR, Bakhle YS, Botting RM. Cyclooxygenase 1 and 2. Ann Rev Pharmacol Toxicol 1998;38:97-120.
48. Willoughby DA, Moore AR, Colville-Nash PR. COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease. Lancet 2000;355:646-8.
49. Sajadieh A, Wendelboe O, Hansen JF, Mortensen LS, for the DAVIT Study Group. Nonsteroidal anti-inflammatory drugs after acute myocardial infarction. Am J Cardiol 1999;83:1263-5.
50. Azar RR, Rinfret S, Theroux P, Stone PH, Dakshinamurthy R, Feng YJ, et al. A randomized placebo-controlled trial to assess the efficacy of anti-inflammatory therapy with methylprednisolone in unstable angina (MUNA trial). Eur Heart J 2000;21:2026-32.
51. Burleigh ME, Babaev VR, Oates JA, Harris RC, Gautam S, Riendeau D, et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation 2002;105:1816-23.
52. Pitt B, Pepine C, Willerson JT. Cyclooxygenase-2 inhibition and cardiovascular events. Circulation 2002;106:167-9.
53. Ridker PM, Cushman M, Stampfer MJ, Tracy RP. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
54. Cyrus T, Sung S, Zhao L, Funk CD, Tang S, Praticò D. Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation 2002;106:1282-7.
55. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group. N Engl J Med 2000;343:1520-8.
56. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonesteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid artritis. The celecoxib long-term arthritis safety study (CLASS): a randomized controlled trial. JAMA 2000;284:1247-55.
57. Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001;104:2280-8.
58. Dalen J. Selective COX-2 inhibitors, NSAIDs, aspirin, and myocardial Infarction. Arch Inter Med 2002; 162:1091-2.
59. Engelhardt G, Homma D, Schlegel K, Utzmann R, Schnitzler C. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favorable gastrointestinal tolerance. Inflamm Res 1995;44:423-33.
60. Ogino K, Hatanaka K, Kawamura M, Katori M, Harada Y. Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1. Pharmacology 1997;55:44-53.
61. Engelhardt G, Bogel R, Schnitzler C, Utzmann R. Meloxicam: influence on arachidonic acid metabolism. Part II: in vivo findings. Biochem Pharmacol 1996;51:29-38.
62. Altman R, Luciardi HL, Muntaner J, Del Río F, Berman SG, López R, et al. Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study. Circulation 2002;106(2):191-5.